BankPlus Trust Department Purchases Shares of 146 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

BankPlus Trust Department purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 146 shares of the company’s stock, valued at approximately $60,000.

A number of other institutional investors have also recently made changes to their positions in IDXX. IFP Advisors Inc lifted its stake in shares of IDEXX Laboratories by 3.6% in the 4th quarter. IFP Advisors Inc now owns 903 shares of the company’s stock valued at $373,000 after purchasing an additional 31 shares during the period. Y Intercept Hong Kong Ltd lifted its stake in shares of IDEXX Laboratories by 265.4% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 9,132 shares of the company’s stock valued at $3,776,000 after purchasing an additional 6,633 shares during the period. Union Bancaire Privee UBP SA acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $1,544,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in shares of IDEXX Laboratories by 13.5% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 20,992 shares of the company’s stock valued at $8,679,000 after purchasing an additional 2,500 shares during the period. Finally, Howard Capital Management Inc. lifted its stake in shares of IDEXX Laboratories by 3.0% in the 4th quarter. Howard Capital Management Inc. now owns 2,304 shares of the company’s stock valued at $953,000 after purchasing an additional 67 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.8 %

IDXX stock opened at $459.86 on Wednesday. The stock’s 50 day simple moving average is $433.24 and its 200 day simple moving average is $451.88. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $37.66 billion, a P/E ratio of 43.10, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDXX. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.